Benefit and costs of individualised medicine in colorectal and non-small-cell lung cancer (NSCLC)
Despite the health economics burden of cancer to society, little research has been done so far with respect to the health economics assessment of cancer care in Germany. Currently, many new and expensive pharmaceuticals, so-called individualised medicines, get approval from the EMA; however, no information regarding their cost-effectiveness is available to date. Therefore, aim of this study is to identify costs and benefits of individualised medicine in colorectal and non-small-cell lung cancer (NSCLC), two of the most common cancer types in Germany.
Funded by the Federal Ministry of Education and Research (BMBF)
Dr. Alexander Kuhlmann